- Home
- IOBT vs IPA Comparison
IOBT vs IPA Comparison
Compare IOBT & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- IPA
- Stock Information
- Founded
- IOBT 2014
- IPA 1983
- Country
- IOBT Denmark
- IPA United States
- Employees
- IOBT N/A
- IPA N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- IPA Health Care
- Exchange
- IOBT Nasdaq
- IPA Nasdaq
- Market Cap
- IOBT 114.6M
- IPA 98.9M
- IPO Year
- IOBT 2021
- IPA 2017
- Fundamental
- Price
- IOBT $1.95
- IPA $1.99
- Analyst Decision
- IOBT Strong Buy
- IPA Strong Buy
- Analyst Count
- IOBT 3
- IPA 2
- Target Price
- IOBT $8.67
- IPA $4.00
- AVG Volume (30 Days)
- IOBT 8.9M
- IPA 1.9M
- Earning Date
- IOBT 08-14-2025
- IPA 09-24-2025
- Dividend Yield
- IOBT N/A
- IPA N/A
- EPS Growth
- IOBT N/A
- IPA N/A
- EPS
- IOBT N/A
- IPA N/A
- Revenue
- IOBT N/A
- IPA $17,744,713.00
- Revenue This Year
- IOBT N/A
- IPA $18.76
- Revenue Next Year
- IOBT N/A
- IPA $32.14
- P/E Ratio
- IOBT N/A
- IPA N/A
- Revenue Growth
- IOBT N/A
- IPA 0.01
- 52 Week Low
- IOBT $0.66
- IPA $0.27
- 52 Week High
- IOBT $2.79
- IPA $3.25
- Technical
- Relative Strength Index (RSI)
- IOBT 56.62
- IPA 45.66
- Support Level
- IOBT $1.53
- IPA $1.86
- Resistance Level
- IOBT $1.77
- IPA $3.25
- Average True Range (ATR)
- IOBT 0.21
- IPA 0.36
- MACD
- IOBT 0.01
- IPA -0.10
- Stochastic Oscillator
- IOBT 33.33
- IPA 9.38
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.